Oral Cannabidiol does not Alter the Subjective, Reinforcing or Cardiovascular Effects of Smoked Cannabis.

Intranasal buprenorphine alone and in combination with naloxone: Abuse liability and reinforcing efficacy in physically dependent opioid abusers.

Intranasal buprenorphine alone and in combination with naloxone: Abuse liability and reinforcing efficacy in physically dependent opioid abusers.

[Anonymous].  2016.  Intranasal buprenorphine alone and in combination with naloxone: Abuse liability and reinforcing efficacy in physically dependent opioid abusers.. Drug and alcohol dependence. 162:190-8.

Opioid withdrawal suppression efficacy of oral dronabinol in opioid dependent humans.

A Pharmacokinetic Study Examining Acetazolamide as a Novel Adherence Marker for Clinical Trials.

The Abuse Potential of Prescription Opioids in Humans-Closing in on the First Century of Research.

Oral cannabidiol does not produce a signal for abuse liability in frequent marijuana smokers.

A randomized placebo-controlled trial of N-acetylcysteine for cannabis use disorder in adults.

Tobacco use during cannabis cessation: Use patterns and impact on abstinence in a National Drug Abuse Treatment Clinical Trials Network study.

Tobacco use during cannabis cessation: Use patterns and impact on abstinence in a National Drug Abuse Treatment Clinical Trials Network study.

[Anonymous].  2018.  Tobacco use during cannabis cessation: Use patterns and impact on abstinence in a National Drug Abuse Treatment Clinical Trials Network study.. Drug and alcohol dependence. 192:59-66.

Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition).

Expression of a Constitutively Active Human Insulin Receptor in Hippocampal Neurons Does Not Alter VGCC Currents.